n-succinimidyl 3-iodobenzoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	124646
SCHEMBL ID	317765
MeSH ID	M0172590

Synonyms (15)

Synonym
91487-18-2
n-succinimidyl 3-iodobenzoate
(2,5-dioxopyrrolidin-1-yl) 3-iodobenzoate
2,5-pyrrolidinedione, 1-((3-iodobenzoyl)oxy)-
ns-m-ib
SCHEMBL317765
RIOSXWBFXSDUDE-UHFFFAOYSA-N
2,5-dioxopyrrolidin-1-yl 3-iodobenzoate
3-iodo-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester
DTXSID70919695
1-[(3-iodobenzoyl)oxy]pyrrolidine-2,5-dione
A1-14521
succinimidyl 3-iodobenzoate
2,5-pyrrolidinedione, 1-[(3-iodobenzoyl)oxy]-
E86087

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (12.50)	18.7374
1990's	3 (37.50)	18.2507
2000's	2 (25.00)	29.6817
2010's	2 (25.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.05 (24.57)
Research Supply Index	2.71 (2.92)
Research Growth Index	4.76 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.41	2	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril: reagent for protein iodinations; structure	2.41	2
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid: structure given in first source. DOTA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 7 and 10 of a twelve-membered ring are each substituted with a carboxymethyl group.	2.07	1	azamacrocycle	chelator; copper chelator
f-chemotactic peptide F-chemotactic peptide: potent chemoattractant for human neutrophils	2.03	1
n-succinimidyl-3-(tri-n-butylstannyl)benzoate [no description available]	2.1	1
n-succinimidyl 4-iodobenzoate N-succinimidyl 4-iodobenzoate: structure given in first source	1.97	1
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	2.03	1	tripeptide
tin [no description available]	2.07	1	carbon group element atom; elemental tin; metal atom	micronutrient

Condition	Relationship Strength	Studies
Astrocytoma, Grade IV [description not available]	2.07	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.07	1
E coli Infections [description not available]	2.03	1
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	2.03	1
Cancer of Pancreas [description not available]	1.98	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	1.98	1
Germinoblastoma [description not available]	1.97	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	1.97	1

chemdatabank.com